The economic value of insulin glargine 300  U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspective

CONCLUSIONS: The economic value of increased utilization of Gla-300 was driven by the reduction in HCRU, costs and market shares assumptions. Budgetary reductions were achieved by switching patients from long-acting BIs to Gla-300.PMID:37916295 | DOI:10.1080/13696998.2023.2277058

Source: Journal of Medical Economics - November 2, 2023 Category: Health Management Authors: Ekaterina Ponomareva Luke Schmerold Srinivas Sss Ronald Preblick Seojin Park Laura Wilson Andrew Revel Source Type: research